• MabSelect SuRe 70 and MabSelect PrismA X resins to set new standards in affordability and productivity
• Cytiva's expanded resin portfolio will support advances in the mAb and biosimilar markets
• MabSelect resins are based on the renewable raw material, agarose

With the growth and transformation of the mAb market, particularly with the recent rapid rise of biosimilars, a one-size-fits-all approach to protein purification is no longer viable. To address this, Cytiva developed two new protein A resins: the MabSelect SuRe 70 and the MabSelect PrismA X.

Sofie Stille, Vice President and General Manager, Resins and Technologies, Cytiva, says: “The different stages of drug development require different purification needs. As more molecules are being brought to clinic, we wanted to provide our customers with innovative and cost-effective options regardless of stage. These new resins offer affordability without sacrificing quality.”

With these new resins, Cytiva has expanded its comprehensive protein A resin portfolio with additional options to further help customers reduce manufacturing expenses and increase flexibility, while maintaining the same high-quality customers expect.

Key features of the new products:

• MabSelect SuRe 70: This resin has high dynamic binding capacity (DBC). It combines Cytiva’s industry-leading quality with affordability, addressing the needs of clinical stages.
• MabSelect PrismA X: Designed for cost-efficiency, this resin offers highest DBC of all MabSelect resins and excellent durability for robust mAb capture.

The need for affordability is especially relevant in the purification stage for preclinical or clinical production, where 20 batches are run at most. Whereas in commercial production, speed and performance becomes crucial.

Sofie Stille adds: “At whatever stage or scale a customer is at, we can offer solutions that fit based on speed, performance, or affordability, each sustainably designed.”

Committed to security of supply and sustainability

MabSelect resins are based on agarose, a renewable raw material, aligning with Cytiva’s sustainability commitments. Since 2022, Cytiva owns its agarose manufacturing and processing plant in Denmark, geographically close to the Swedish resins manufacturing site. Cytiva has also taken steps to further boost its security of supply by adding a second manufacturing site located in North America. The Muskegon, Michigan site has undergone complete renovations and is on track for tech transfer.

By strengthening the offering of protein A resins in clinical production, Cytiva continues to build on global representation and support the mAb industry with innovative, reliable, and sustainable solutions.